ADMA Biologics Securities Class Action
ADMA Biologics · ADMA Biologics securities · Ongoing Litigation
About this case
The complaint alleges that ADMA Biologics and certain executives violated federal securities laws by making materially false or misleading statements or omissions concerning an undisclosed related-party transaction, channel stuffing, internal controls, and the company’s business prospects. The action is pending in federal court, and the stated August 10, 2026 deadline to seek appointment as lead plaintiff has passed.
Case overview
- Defendant company
- ADMA Biologics
- Product or service
- ADMA Biologics securities
- Case name
- Mazzarino v. ADMA Biologics, Inc., et al.
- Court case number
- 26-cv-04793
- Case status
- Ongoing Litigation
- Lawsuit type
- Securities
- Reported harm
- Misrepresentation
Important dates
- Kahn Swick & Foti investor inquiry
Participation information
Kahn Swick & Foti investor inquiry
The law firm invited information from investors concerning losses in ADMA Biologics securities during the stated class period.
Contact Kahn Swick & Foti through its case webpage for more information.
- Type
- Law Firm Signup
- Status
- Deadline passed
- Reported proof requirement
- Unclear
Sources
- ADMA Biologics Securities Class Action
Barchart.com ·
- ADMA Biologics Securities Class Action
Barchart.com ·
- ADMA Biologics Securities Class Action
Barchart.com ·
- ADMA Biologics Securities Class Action
Barchart.com ·
- ADMA Biologics Securities Class Action
Barchart.com ·
- ADMA Biologics Securities Class Action
Benzinga ·
- ADMA Biologics Securities Class Action
Barchart.com ·
- ADMA Biologics Securities Class Action
Barchart.com ·